+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Anthrax Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023-2028)

  • PDF Icon


  • 111 Pages
  • April 2023
  • Region: Global
  • Mordor Intelligence
  • ID: 4896056
The anthrax treatment market is expected to register a CAGR of 7.8% over the forecast period.

The COVID-19 pandemic caused disruptions in the supply chains and treatment protocols for pharmaceuticals around the world, which also influenced the global antibiotics and immunoglobulins specific to the anthrax market. On a global scale, however, it appeared infrequently in developed countries compared to developing and underdeveloped nations. For instance, as per the report published by the Annals of Medicine and Surgery in September 2022, Zimbabwe and southern Kenya have seen anthrax outbreaks with significant morbidity and low mortality during the COVID-19 pandemic. Initiatives undertaken within the countries to lower the spread of diseases have positively impacted the market’s growth. For instance, telecommunications firms were employed by countries including Nigeria, Zambia, So Tomé and Principe, and Burkina Faso to promote the supply of information about preventative and control measures. Thus, there was a significant impact on the treatment of anthrax in developing regions during the pandemic that helped the market grow. As per the analysis, the reinstatement of the supply chains and healthcare facilities is another factor that is expected to contribute to the market under consideration eventually reaching its full potential in the post-pandemic phase.

Furthermore, the anthrax treatment market will show rapid growth due to the increase in research funding and the development of novel therapies for the treatment of anthrax. Along with the aforementioned considerations, the emergence of new anthrax animal cases in various regions also supports market expansion as human exposure to animal spores might result in anthrax.

The increasing number of novel developments for the innovative and effective treatment of anthrax is one of the major factors expected to boost the growth of the anthrax treatment market. There has been a surge in the development of novel therapies due to the rising threat of exposure to Bacillus anthracis among civilian populations and military forces. For instance, in December 2021, USAMRIID researchers found a way to prevent mice from contracting the lethal disease anthrax by altering an enzyme generated by the bacterium that causes it. Their conclusion could result in the development of new antibiotics for various bacterial illnesses as well as a potential therapeutic approach for multidrug-resistant anthrax strains. The growing threat of exposure has thus led to the development of new therapies for anthrax treatment, which will have a positive impact on the growth of the anthrax treatment market in the near future.

Similarly, the new cases of anthrax among animals influence the market as it spreads to humans through animal spores. For instance, according to the public notice published by the government of Sierra Leone in May 2022, new anthrax disease cases were discovered among animals in the northern district of Port Loko in the city of Sierra Leone, West Africa. This may increase the spread to humans and increase the demand for anthrax treatment, which is expected to drive the growth of the market during the study period.

However, the high cost associated with diagnostic treatment is expected to restrain the growth of the anthrax treatment market over the analysis period.

Anthrax Treatment Market Trends

Inhalation Anthrax Segment is Expected to Dominate During the Forecast Period

Inhalation anthrax is considered to be the deadliest form of anthrax. Infection usually develops within a week after exposure, but it can take up to two months. Inhalation anthrax starts primarily in the lymph nodes in the chest before spreading throughout the rest of the body, ultimately causing severe breathing problems and shock. Without treatment, inhalation of anthrax is almost always fatal.

The inhalation anthrax segment is expected to hold a major market due to the development of new products and various collaborations between the companies. For instance, as per the study report published by the MDPI journal in February 2022, they developed a recombinant human-like humanized antibody, 35PA83 6.20, that binds the protective antigen and inhibits the production of anthrax toxins in white New Zealand rabbits that have been intranasally exposed to the deadly 9602 strain. These advanced developments in the treatment of anthrax are expected to have a positive impact on the market segment's growth.

Furthermore, the additional funding for the development of various products for the treatment of inhaled anthrax propels the growth of the segment. For instance, in September 2021, Paratek Pharmaceuticals was awarded additional funding under the BARDA contract to advance the development of NUZYRA (omadacycline) for post-exposure prophylaxis (PEP) and the treatment of pulmonary anthrax.

Hence, all the above-mentioned factors and funding are expected to bolster the segment’s growth throughout the forecast period.

North America is Anticipated to Dominate the Anthrax Treatment Market

North America is expected to dominate the global market owing to high government funding, supportive strategies, and the presence of key players in this region. Anthrax is rare in the United States, but sporadic outbreaks do occur in wild and domestic grazing animals, such as cattle or deer. Therefore, in the United States, yearly vaccination of livestock is recommended in areas where animals have had anthrax in the past. In the United States, a few people have developed anthrax while making traditional African drums from the skins of infected animals. However, all types of anthrax infections can be treated with antibiotics, including intravenous antibiotics and prescribed medications that are given to patients based on their medical histories. Anthrax Vaccine Adsorbed (AVA) or BioThrax is the anthrax vaccine indicated for active immunization for the prevention of disease caused by Bacillus anthracis in people aged 18-65 that are at a high risk of exposure. The vaccine has been licensed since 1970 and is currently manufactured by Emergent BioSolutions, Inc.

Moreover, factors such as initiatives by organizations like the CDC supporting the development of novel therapies for the treatment of anthrax drive market growth in the Americas. For instance, as per the report published by the American Chemical Society in September 2022, the team has taken a step toward the development of a therapeutic that can treat the infection in mice without antibiotics. According to the above-mentioned study, engineered Fc-fusion of a capsule-degrading enzyme is used as the new treatment option for anthrax. As a result, new advancements in the region during the anticipated forecast period will lead to market growth.

Similarly, new contracts for products from companies are expected to boost the market growth. For instance, in April 2022, Heat Biologics, Inc. (renamed NightHawk Biosciences) and Elusys Therapeutics finalized a contract with the Canadian government to deliver ANTHIM (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack.

Hence, all the above-mentioned factors are anticipated to augment the growth of anthrax treatment in the North American region.

Anthrax Treatment Market Competitor Analysis

The anthrax treatment market is fragmented due to the availability of more treatment options from various market players. There are a considerable number of companies developing therapeutics that are quite intense. Factors such as the increase in the development of new therapies and an increase in research funding will provide considerable growth opportunities for anthrax treatment manufacturers. The major players include Nighthawk Biosciences, Inc. (Elusys Therapeutics, Inc.), Almirall, LLC, Emergent, Paratek Pharmaceuticals, Inc., GSK plc, Teva Pharmaceuticals Industries Ltd., Bayer AG, Pfizer Inc., and Lilly.

Additional benefits of purchasing the report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

This product will be delivered within 2 business days.

Table of Contents

1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Research Funding
4.2.2 Development of Novel Therapies for Treatment of Anthrax
4.3 Market Restraints
4.3.1 High Cost Associated with Diagnostic Treatment
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Anthrax Type
5.1.1 Cutaneous Anthrax
5.1.2 Inhalation Anthrax
5.1.3 Gastrointestinal Anthrax
5.1.4 Injection Anthrax
5.2 By Drug Class
5.2.1 Antibiotics
5.2.2 Immunoglobulins
5.2.3 Others
5.3 By Distribution Channel
5.3.1 Hospitals
5.3.2 Pharmacies
5.3.3 Other Distribution Channels
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.4.5 South America Brazil Argentina Rest of South America
6.1 Company Profiles
6.1.1 Almirall, LLC
6.1.2 Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
6.1.3 Emergent
6.1.4 Paratek Pharmaceuticals, Inc.
6.1.5 Pfizer Inc.
6.1.6 Bayer AG
6.1.7 GSK plc
6.1.8 Teva Pharmaceutical Industries Ltd.
6.1.9 Lilly

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Almirall, LLC
  • Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
  • Emergent
  • Paratek Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bayer AG
  • GSK plc
  • Teva Pharmaceutical Industries Ltd.
  • Lilly